Peramivir injection in the treatment of acute influenza: a review of the literature

References

• RuuskanenOLahtiEJenningsLCMurdochDRViral pneumoniasLancet201137797731264127521435708
   PubMed Web of Science ®Google Scholar
• FioreAEUyekiTMBroderKPrevention and control of influenza with vaccinesMMWR Morb Mortal Wkly Rep201059RR–816220075837
   PubMedGoogle Scholar
• World Health Organization (WHO)Influenza (seasonal). Fact Sheet; March 2014Geneva, SwitzerlandWorld Health Organization2014 Available from: http://www.who.int/mediacentre/factsheets/fs211/en/Accessed June 23, 2014
   Google Scholar
• GirardMPCherianTPervikovYKienyMPA review of vaccine research and development: human acute respiratory infectionsVaccine200523505708572416154667
   PubMed Web of Science ®Google Scholar
• ShresthaSSSwerdlowDLBorseRHEstimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–2010)Clin Infect Dis201152Suppl 1S75S8221342903
   PubMed Web of Science ®Google Scholar
• LouieJKAcostaMWinterKthe California Pandemic (H1N1) Working GroupFactors associated with death or hospitalization due to pandemic 2009 influenza A (H1N1) infection in CaliforniaJAMA2009302171896190219887665
   PubMed Web of Science ®Google Scholar
• HaydenFDeveloping new antiviral agents for influenza treatment: what does the future hold?Clin Infect Dis200948Suppl 1S3S1319067613
   PubMed Web of Science ®Google Scholar
• YuYGargSPatriciaAPeramivir use for treatment of hospitalized patients with influenza A (H1N1) pdm09 under emergency use authorization, October 2009–June 2010Clin Infect Dis201255181522491506
   PubMed Web of Science ®Google Scholar
• SorbelloAJonesSCCarterWEmergency use authorization for intravenous peramivir: evaluation of safety in the treatment of hospitalized patients infected with 2009 H1N1 influenza A virusClin Infect Dis20125511722491501
   PubMed Web of Science ®Google Scholar
• HataAAkashi-UedaRTakamatsuKMatsumuraTSafety and efficacy of peramivir for influenza treatmentDrug Des Devel Ther2014820172038
   PubMed Web of Science ®Google Scholar
• IsonMGOptimizing antiviral therapy for influenza: understanding the evidenceExpert Rev Anti Infect Ther201513441742525695406
   PubMed Web of Science ®Google Scholar
• McLaughlinMMSkoglundEWIsonMGPeramivir: an intravenous neuraminidase inhibitorExpert Opin Pharmacother201516121889190026153242
   PubMed Web of Science ®Google Scholar
• US Food Drug AdministrationFDA approves Rapivab to treat flu infectionSilver Spring, MDUS Food and Drug Administration Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm427755.htmAccessed June 23, 2015
   Google Scholar
• MosconaANeuraminidase inhibitors for influenzaN Engl J Med2005353131363137316192481
   PubMed Web of Science ®Google Scholar
• LiWEscarpePAEisenbergEJIdentification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071Antimicrob Agents Chemother19984236476539517946
   PubMed Web of Science ®Google Scholar
• HaydenFGTreanorJJBettsRFSafety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenzaJAMA199627542952998544269
   PubMed Web of Science ®Google Scholar
• NguyenHTSheuTGMishinVPKlimovAIGubarevaLVAssessment of pandemic and seasonal influenza A (H1N1) virus susceptibility to neuraminidase inhibitors in three enzyme activity inhibition assaysAntimicrob Agents Chemother20105493671367720585136
   PubMed Web of Science ®Google Scholar
• MendelDBTaiCYEscarpePAOral administration of a prodrug of the influenza virus neuraminidase inhibitor GS 4071 protects mice and ferrets against influenza infectionAntimicrob Agents Chemother19984236406469517945
   PubMed Web of Science ®Google Scholar
• BabuYSChandPBantiaSBCX-1812 (RWJ-270201): discovery of a novel, highly potent, orally active, and selective influenza neuraminidase inhibitor through structure-based drug designJ Med Chem200043193482348611000002
   PubMed Web of Science ®Google Scholar
• BantiaSArnoldCSParkerCDAnti-influenza virus activity of peramivir in mice with single intramuscular injectionAntiviral Res2006691394516325932
   PubMed Web of Science ®Google Scholar
• BantiaSUpshawRBabuYSCharacterization of the binding affinities of peramivir and oseltamivir carboxylate to the neuraminidase enzymeAntiviral Res201191328829121722670
   PubMed Web of Science ®Google Scholar
• MinenoTMillerMJStereoselective total synthesis of racemic BCX-1812 (RWJ-270201) for the development of neuraminidase inhibitors as anti-influenza agentsJ Org Chem200368176591659612919021
   PubMed Web of Science ®Google Scholar
• CastilloRHollandLEBoltzDAPeramivir and its use in H1N1 influenzaDrugs Today (Barc)201046639940820571608
   PubMed Web of Science ®Google Scholar
• BeigelJHarmonLACollisPJPharmacokinetics and safety evaluations of escalating doses of peramivir administered intravenously in healthy volunteersPresented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)September 17–20, 2007Chicago, IL Abstract A-1408
   Google Scholar
• BarrosoLTreanorJGubarevaLEfficacy and tolerability of the oral neuraminidase inhibitor in experimental human influenza: randomized, controlled trials for prophylaxis and treatmentAntivir Ther200510890191016430195
   PubMed Web of Science ®Google Scholar
• AtieeGCollisPMcCulloughADoboSElderJSheridanBSingle dose injections of iv and im peramivir are bioequivalent and well toleratedPoster presented at: Interscience Conference on Antimicrobial Agents ChemotherapySeptember 5–9, 2014Washington, DC
   Google Scholar
• MatsuoYIshibashiTHollisterASWajimaTPopulation pharmacokinetics of peramivir in healthy volunteers and influenza patientsAntimicrob Agents Chemother201559116755676226282420
   PubMed Web of Science ®Google Scholar
• ZhangDDuAZhangLPharmacokinetics of peramivir after single intravenous doses in healthy Chinese subjectsXenobiotica201445323924325231091
   PubMed Web of Science ®Google Scholar
• SatoMItoMSuzukiSInfluenza viral load and peramivir kinetics after single administration and proposal of regimens for peramivir administration against resistant variantsAntimicrob Agents Chemother20155931643164925547357
   PubMed Web of Science ®Google Scholar
• BentleyMLHollisteraASHansenbACSmithJACainJSPeramivir pharmacokinetics in a patient receiving continuous veno-venous hemodiafiltration during the 2009 H1N1 influenza A pandemicInt J Clin Pharm Ther2014521211051111
   Web of Science ®Google Scholar
• TangXHeHSunBARDS associated with pneumonia caused by avian influenza A H7N9 virus treated with extracorporeal membrane oxygenationClin Respir J20159338038424725670
   PubMed Web of Science ®Google Scholar
• GovorkovaEALenevaIAGoloubevaOGComparison of efficacies of RWJ-270201, zanamivir, and oseltamivir against H5N1, H9N2, and other avian influenza virusesAntimicrob Agents Chemother200145102723273211557461
   PubMed Web of Science ®Google Scholar
• FarooquiAHuangLWuSAssessment of antiviral properties of peramivir agains H7N9 avian influenza virus in an experimental mouse modelAntimicrob Agents Chemother201559127255726426369969
   PubMed Web of Science ®Google Scholar
• DapatCKondoHDapatICNeuraminidase inhibitor susceptibility profile of pandemic and seasonal influenza viruses during the 2009–2010 and 2010–2011 influenza seasons in JapanAntiviral Res201399326126923791870
   PubMed Web of Science ®Google Scholar
• LeangSKKwokSSullivanSGPeramivir and laninamivir susceptibility of circulating influenza A and B virusesInfluenza Other Respir Viruses20138213513924734292
   PubMed Web of Science ®Google Scholar
• BazMAbedYBoivinGCharacterization of drug-resistant recombinant influenza A/H1N1 viruses selected in vitro with peramivir and zanamivirAntiviral Res200774215916217137644
   PubMed Web of Science ®Google Scholar
• TakashitaEMeijerALackenbyAGlobal update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013–2014Antiviral Res2015117273825721488
   PubMed Web of Science ®Google Scholar
• TakashitaEFujisakiSKishidaNCharacterization of neuraminidase inhibitor-resistant influenza A (H1N1) pdm09 viruses isolated in four seasons during pandemic and post-pandemic periods in JapanInfluenza Other Respir Viruses2013761390139923745712
   PubMed Web of Science ®Google Scholar
• MemoliMJHrabalRJHassantoufighiAEichelbergerMCTaubenbergerJKRapid selection of oseltamivirand peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hostsClin Infect Dis20105091252125520345239
   PubMed Web of Science ®Google Scholar
• TakashitaEEjimaMItohRA community cluster of influenza A (H1N1) pdm09 virus exhibiting cross-resistance to oseltamivir and peramivir in Japan, November to December 2013Euro Surveill201419116
   Google Scholar
• NguyenHTTrujilloAASheuTGAnalysis of influenza viruses from patients clinically suspected of infection with an oseltamivir resistant virus during the 2009 pandemic in the United StatesAntiviral Res201293338138622330888
   PubMed Web of Science ®Google Scholar
• HurtACHardieKWilsonNJCommunity transmission of oseltamivir-resistant A (H1N1) pdm09 influenzaN Engl J Med2011365262541254222204735
   PubMed Web of Science ®Google Scholar
• SleemanKMishinVPGuoZAntiviral susceptibility of variant influenza A (H3N2) viruses isolated in the United States from 2011 to 2013Antimicrob Agents Chemother20145842045205124449767
   PubMed Web of Science ®Google Scholar
• FarrukeeRMosseJHurtACReview of the clinical effectiveness of the neuraminidase inhibitors against influenza B virusesExpert Rev Anti Infect Ther201311111135114524093683
   PubMed Web of Science ®Google Scholar
• BioCryst PharmaceuticalsEvaluation of the efficacy and safety of peramivir in subjects with uncomplicated acute influenza Available from: https://clinicaltrials.gov/ct2/show/NCT0419263. NLM identifier: NCT0419263Accessed November 30, 2015
   Google Scholar
• AtieeGLaughlinATellierGVirologic analysis of influenza viruses after therapy with a single intramuscular dose of the neuraminidase inhibitor peramivir versus placebo in patients with influenza in the outpatient settingPresented at: 49th Annual Meeting of the Infectious Diseases Society of AmericaOctober 20–23, 2011Boston, MA
   Google Scholar
• KohnoSKidaHMizuguchiMShimadaJEfficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infectionAntimicrob Agents Chemother201054114568457420713668
   PubMed Web of Science ®Google Scholar
• KohnoSKidaHMizuguchiMIntravenous peramivir for treatment of influenza A and B virus infection in high-risk patientsAntimicrob Agents Chemother20115562803281221464252
   PubMed Web of Science ®Google Scholar
• KohnoSYenMYCheongHJComparison of single-dose intravenous peramivir with oral oseltamivir in patients with seasonal influenza virus infection: a phase III randomized, double-blind studyAntimicrob Agents Chemother201155115267527621825298
   PubMed Web of Science ®Google Scholar
• IsonMGHuiDSClezyKA clinical trial of intravenous peramivir compared with oral oseltamivir for the treatment of seasonal influenza in hospitalized adultsAntivir Ther201318565166123111657
   PubMed Web of Science ®Google Scholar
• HernandezJEAdigaRArmstrongRClinical experience in adults and children treated with intravenous peramivir for 2009 influenza A (H1N1) under an emergency IND program in the United StatesClin Infect Dis2011526696706
   Web of Science ®Google Scholar
• de JongMDIsonMGMontoASEvaluation of intravenous peramivir for treatment of influenza in hospitalized patientsClin Infect Dis20145912e172e18525115871
   PubMed Web of Science ®Google Scholar
• YoshinoYSeoKKogaIKitazawaTOtaYClinical efficacy of peramivir in adult patients with seasonal influenza during the winter of 2012 in JapanClin Respir J20149222823224612842
   PubMed Web of Science ®Google Scholar
• IsonMGFraizJHellerBIntravenous peramivir for treatment of influenza in hospitalized patientsAntivir Ther201419434936123985625
   PubMed Web of Science ®Google Scholar
• SugayaNKohnoSIshibashiTWajimaTTakahashiTEfficacy, safety, and pharmacokinetics of intravenous peramivir in children with 2009 pandemic A (H1N1) influenza virus infectionAntimicrob Agents Chemother201256136937722024821
   PubMed Web of Science ®Google Scholar
• ShobugawaYSaitoRSatoIClinical effectiveness of neuraminidase inhibitors –oseltamivir, zanamivir, laninamivir, and peramivir – for treatment of influenza A (H3N2) and A (H1N1) pdm09 infection: an observational study in the 2010–2011 influenza season in JapanJ Infect Chemother201218685886422644080
   PubMed Web of Science ®Google Scholar
• HikitaTHikitaHHikitaFHikitaNHikitaSClinical effectiveness of peramivir in comparison with other neuraminidase inhibitors in pediatric influenza patientsInt J Pediatr2012201214
   Google Scholar
• SugayaNShinjohMMitamuraKTakahashiTVery low pandemic influenza A (H1N1) 2009 mortality associated with early neuraminidase inhibitor treatment in Japan: analysis of 1,000 hospitalized childrenJ Infect201163428829421722665
   PubMed Web of Science ®Google Scholar
• LouieJKYangSSamuelMCUyekiTMSchechterRNeuraminidase inhibitors for critically ill children with influenzaPediatrics20131326e1539e154524276847
   PubMed Web of Science ®Google Scholar
• LouieJKYangSYenCAcostaMSchechterRUyekiTMUse of intravenous peramivir for treatment of severe influenza A (H1N1) pdm09PLoS One201276e4026122768265
   PubMed Web of Science ®Google Scholar
• DunningJBaillieJKCaoBAntiviral combinations for severe influenzaLancet Infect Dis201414121259127025213733
   PubMed Web of Science ®Google Scholar
• AtieeGLasseterKBaughmanSAbsence of pharmacokinetic interaction between intravenous peramivir and oral oseltamivir or rimantadine in humansJ Clin Pharmacol20125291410141921960669
   PubMed Web of Science ®Google Scholar
• Peramivir® (Rapivab) [package insert]Durham, NCBioCryst Pharmaceuticals, Inc2014
   Google Scholar
• DoboSMElderJCollisPSafety of peramivir in hospitalized influenzaPoster #1169 presented at: 53rd Annual Meeting of the Infectious Diseases Society of AmericaOctober 8–11Philadelphia, PA
   Google Scholar
• KomedaTIshiiSItohYPost-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (I): a drug use investigationJ Infect Chemother2014201168969525131292
   PubMed Web of Science ®Google Scholar
• KomedaTIshiiSItohYPost-marketing safety and effectiveness evaluation of the intravenous anti-influenza neuraminidase inhibitor peramivir (II): a pediatric drug use investigationJ Infect Chemother201421319420125523716
   PubMed Web of Science ®Google Scholar
• HayashiKIwasaKMorinagaAOnoKYamadaMExacerbation of myasthenia gravis by intravenous peramivirMuscle Nerve201551693593625656959
   PubMed Web of Science ®Google Scholar
• Harada-ShiradoKIkedaKFurukawaMSevere immune thrombocytopenia possibly elicited by the anti-influenza viral agent peramivirIntern Med201453202369237125318805
   PubMed Web of Science ®Google Scholar
• ArianoRESitarDSZelenitskySAEnteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenzaCMAJ2010182435736320159892
   PubMed Web of Science ®Google Scholar
• TaylorWRThinhBNAnhGTOseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenzaPLoS One2008310e3410.1618923671
   PubMed Web of Science ®Google Scholar